Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular assist device (LVAD). Abbott announced the same day it has the capacity to meet increased demand for LVADs as Medtronic leaves the market.
Feature | Ventricular Assist Devices (VAD) | By Dave Fornell, Editor
Medtronic Ends Sales of HVAD Ventricular Assist System

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular ...

Home July 08, 2021
Home
The Carmat system, an experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can adjust to the changing needs of patients treated for end-stage heart failure. Outcomes in the first series of patients managed with the new heart replacement pump in Auto-Mode are presented in the journal of the American Society for Artificial Internal Organs (ASAIO). 
News | Artificial Heart
Carmat Artificial Heart Shows Promising Automatic Regulation of Blood Flow

June 18, 2021 – An experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can ...

Home June 23, 2021
Home
NIVAHF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients
News | Heart Failure
VoluMetrix's NIVA|HF for Heart Failure Patients Designated as Breakthrough Device by U.S. FDA

June 15, 2021 — VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital ...

Home June 15, 2021
Home
Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.
Feature | ACC | By Dave Fornell, Editor
Key Cardiology Technology Takeaways at ACC 2021

Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 Americ ...

Home June 08, 2021
Home
The Aortix intra-aortic axial flow pump offers hemodynamic support to relieve some of the heart’s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.
News | Heart Failure
Cardiologists at Henry Ford Are First in U.S. to Implant Aortix Heart Pump to Treat Heart Failure

June 7, 2021 – Cardiologists at Henry Ford Hospital are first in the U.S. and second in the world to implant a ...

Home June 07, 2021
Home
RAFT-AF study showed type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart  heart and atrial fibrillation. #ACC21 #ACC2021
News | Heart Failure
Type of Heart Failure May Influence Optimal Approach for AFib Rhythm Control Versus Rate Control Strategy

May 19, 2021 — Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on ...

Home May 19, 2021
Home
The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF
News | Heart Failure
GALACTIC-HF Shows Omecamtiv Mecarbil Brings Greater Benefits for Severe Heart Failure

May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a ...

Home May 18, 2021
Home
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21. #ACC #ACC21 #ACC2021
News | Coronavirus (COVID-19)
Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients

May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly ...

Home May 18, 2021
Home
The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor. #ACC21 #ACC2021
News | Heart Failure
Sacubitril/Valsartan Does Not Outperform ACE Inhibitor in Preventing Heart Failure After Heart Attack

May 15, 2021 — The combination heart failure drug sacubitril/valsartan (Entresto) did not significantly reduce the rate ...

Home May 15, 2021
Home
Estimates of excess deaths, defined as the number of persons who have died from all causes, above the expected number of deaths for a given place and time, can provide a comprehensive account of mortality likely related to the COVID-19 pandemic, including deaths that are both directly and indirectly associated with COVID-19
News | Coronavirus (COVID-19)
CDC Update on Excess Deaths Associated with the COVID-19 Pandemic

May 13, 2021 — Estimates of excess deaths, defined as the number of persons who have died from all causes, above the ...

Home May 13, 2021
Home
The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.
Feature | Stem Cell Therapies | By Simon H. Stertzer, M.D.
Is Cardiac Cell Therapy Worth Another Look?

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections ...

Home May 11, 2021
Home
The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE) have joined the International Contrast Ultrasound Society (ICUS) in recognizing the relatively low risk and important clinical benefits of ultrasound contrast agents (UCAs), which are used routinely around the world to help detect heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adul
News | Contrast Media
Medical Societies Support Safety and Benefits of Ultrasound Contrast Agents

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Home May 11, 2021
Home
Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a previous history of heart disease or cardiovascular risk factors, a new Mount Sinai study shows. 
News | Heart Failure
Patients Hospitalized With COVID-19 Have a Small Risk of Heart Failure

May 11, 2021 — Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a ...

Home May 11, 2021
Home
Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology
News | Heart Failure
Socioeconomic Disparities Associate With Epigenetics and Heart Failure Outcomes

April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States. Heart failure disproportio ...

Home April 26, 2021
Home
COVID-19 disrupted all aspects of science and medicine and unmasked striking disparities and opportunities for transformation. Coronavirus impact this past year is expected to result in a massive rise in new cases of chronic health conditions, including cardiolvascular disease and heart failure.
News | Coronavirus (COVID-19)
Tsunami of Chronic Health Conditions Expected Due to COVID-19 Disruption of Healthcare

April 6, 2021 — A tsunami of chronic health conditions as a result of the COVID-19 (SARS-CoV-2) pandemic, especially car ...

Home April 07, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now